pharma · Age-related Macular Degeneration · Neovascular Age-related Macular Degeneration · OTLK
Outlook Therapeutics NL
Outlook Therapeutics NL B. V.
NovaPharmaNews editorial coverage mentioning Outlook Therapeutics NL — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- Cranbury, USA
- Founded
- 2011
- Employees
- 59
- Programs
- 2
- Drugs
- 3
- Patents
- 2
News & analysis
NovaPharmaNews articles mentioning Outlook Therapeutics NL — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Outlook Therapeutics NL — regulatory, clinical, and market analysis.
Outlook Therapeutics Resubmits LYTENAVA BLA to FDA, Initiating 60-Day Review
Outlook Therapeutics has resubmitted its Biologics License Application (BLA) for LYTENAVA (bevacizumab-vikg) to the FDA, initiating a 60-day Class 1 review. This marks a critical step for the drug's potential approval in treating neovascular age-related macular degeneration (nAMD).
This Week’s Biopharma News: New Approvals, Appeals, and AI
This week's biopharma news highlights significant FDA approvals for Datroway and Hepcludex, a key appeal win for Outlook regarding bevacizumab, and promising Phase 3 data for BioMarin's VOXZOGO. The evolving landscape also sees increased integration of AI in drug development and regulatory processes.